Mindfully Curated
Last week, during the UP.Summit at Florida’s Kennedy Space Center, Zipline announced a $1.5 billion raise at a $21.5 billion post-money valuation, with participation from ARK Invest. The world’s largest drone delivery service, with 150 million commerci…
Huge letters spelling out “Craig W” now cover a portion of petroglyph depicting animals.
This year’s honorees were artist Vija Celmins and filmmaker Denis Villeneuve, while Rosé performed during the festivities.
Maria Cristina Terzaghi, a leading Caravaggio scholar, reportedly found the painting, missing for nearly two centuries, in the back room of a Paris gallery.
Experts carrying out emergency conservation work found carved rock thrones, painted walls, and an almost intact jar featuring incised figures.
It’s a smart move to buy Micron’s shares after their recent pullback.
In response, the museum claimed she wiped a cellphone containing records potentially relevant to Sasha Suda’s wrongful termination lawsuit.
A new NASA contract could be worth $10 billion — or $15 billion — to Voyager Technologies (and others).
Management outlines interim analysis timing and new survival data plans.
Fiber coverage hits 50% of its footprint as hyperscaler demand accelerates.
Reimbursed treatments are steadily displacing discounted programs.
The rule boils down to two tests. Would the stock still pass them at today’s price?
AI-related stocks rallied, and Elon Musk’s Terafab has high ambitions.
A delayed multiyear deal and memory market pressure tested an otherwise strong quarter.
Quality equity outflows weighed, but fixed income and ETFs kept momentum.
CoreWeave and Nebius have sold off hard, and this week’s earnings could show how much the midterm results and higher borrowing costs are weighing on their growth plans.
A $1 million nest egg may seem generous, but on an annual basis, it could leave you short of your goals.
Major indexes fell hard last week, but history has promising news for investors.
Walmart trades at more than 45 times earnings, while Target trades at 17. Here’s why the valuation gap isn’t as simple as it looks.
Management outlined AXPAXLI’s regulatory path and late-stage trial updates.